Approximately 15% of lung cancer tumors are caused by a mutation in a growth receptor called EGFR. An effective drug can kill most of the cancer cells, but the tumor eventually grows back. Researchers investigated the molecular mechanisms behind this relapse. They discovered that some of the cells were resistant to the EGFR treatment; they survived using a parallel pathway.